Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightThis review highlights that the intracellular RAS may have prominent roles in developing potential treatment strategies for COVID-19.
📌 3 Maddede Bu Makale
Özet
Severe acute respiratory syndrome-Coronavirus-2 (SARS-CoV-2) passes into cells through binding the angiotensin-converting enzyme-2 (ACE-2). While many scientists worldwide are trying to understand the physiopathological mechanisms of the disease and its relationship with other diseases, they are trying to find drugs that can treat Coronavirus disease-2019 (COVID-19). It is reported that the incidence of COVID-19 increases in cardiovascular diseases and associated conditions such as diabetes mellitus and hypertension in studies. That is why a large number of scientists are now questioning the use of renin-angiotensin-aldosterone system (RAS) antagonists, angiotensin-2 (Ang-2) receptor antagonists (angiotensin receptor blockers), and ACEs in COVID-19 patients. When all these facts are considered together, their potential effects may be more significant. Some researchers stated that RAS inhibitors might amplify COVID-19 severity. Per the classical knowledge, ACE-2 regulates RAS by converting Ang2 to angiotensin-(1-7), which has antioxidant, vasodilatory, anti-inflammatory, and protective effects on many cell types, especially cardiomyocytes and vascular cells. Local and systemic RAS components such as ACE-2, ACE, and Ang-2 and their interactions are pretty complex. However, numerous reported RAS substrates and enzymes are synthesized intracellularly in many cell types. This review highlights that the intracellular RAS may have prominent roles in developing potential treatment strategies for COVID-19.